User login
Dr Javed Butler, from the University of Mississippi Medical Center, reports on key presentations on heart failure from the 2021 annual meeting of the American Heart Association.
Dr Butler starts with the EMPULSE trial, which looked at the use of empagliflozin in hospitalized patients with acute heart failure. The study found that patients randomly assigned to empagliflozin had a 36% chance of improved outcomes by 3 months.
He next looks at two reports from the EMPEROR-Preserved trials, which examined the effects of empagliflozin on patients with ejection fraction greater than 50%. The study found a 17% relative risk reduction in cardiovascular death and a 22% reduction in risk for first heart failure hospitalization. The second EMPEROR report, which examined quality-of-life metrics, found a benefit in favor of empagliflozin over placebo.
Next, Dr Butler discusses the CHIEF-HF trial, in which heart failure patients were randomly assigned to canagliflozin regardless of ejection fraction. Canagliflozin showed benefit in symptom improvement consistently, regardless of patients having diabetes or heart failure with reduced or preserved ejection fraction.
Finally, Dr Butler examined the results of the FIGARO-DKD trial, which studied finerenone in patients with diabetic kidney disease. The study reported a 32% relative risk reduction in heart failure events, and reduced hospitalization and cardiovascular death in patients who had a history of heart failure events and those who did not.
--
Javed Butler, MD, Professor, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi
Javed Butler, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott; Amgen; Array; AstraZeneca; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; CVRx; Janssen; LivaNova; Luitpold; Medtronic; Merck; Novartis; Novo Nordisk; Vifor
Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis; Boehringer-Ingelheim; Eli Lilly; Janssen
Dr Javed Butler, from the University of Mississippi Medical Center, reports on key presentations on heart failure from the 2021 annual meeting of the American Heart Association.
Dr Butler starts with the EMPULSE trial, which looked at the use of empagliflozin in hospitalized patients with acute heart failure. The study found that patients randomly assigned to empagliflozin had a 36% chance of improved outcomes by 3 months.
He next looks at two reports from the EMPEROR-Preserved trials, which examined the effects of empagliflozin on patients with ejection fraction greater than 50%. The study found a 17% relative risk reduction in cardiovascular death and a 22% reduction in risk for first heart failure hospitalization. The second EMPEROR report, which examined quality-of-life metrics, found a benefit in favor of empagliflozin over placebo.
Next, Dr Butler discusses the CHIEF-HF trial, in which heart failure patients were randomly assigned to canagliflozin regardless of ejection fraction. Canagliflozin showed benefit in symptom improvement consistently, regardless of patients having diabetes or heart failure with reduced or preserved ejection fraction.
Finally, Dr Butler examined the results of the FIGARO-DKD trial, which studied finerenone in patients with diabetic kidney disease. The study reported a 32% relative risk reduction in heart failure events, and reduced hospitalization and cardiovascular death in patients who had a history of heart failure events and those who did not.
--
Javed Butler, MD, Professor, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi
Javed Butler, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott; Amgen; Array; AstraZeneca; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; CVRx; Janssen; LivaNova; Luitpold; Medtronic; Merck; Novartis; Novo Nordisk; Vifor
Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis; Boehringer-Ingelheim; Eli Lilly; Janssen
Dr Javed Butler, from the University of Mississippi Medical Center, reports on key presentations on heart failure from the 2021 annual meeting of the American Heart Association.
Dr Butler starts with the EMPULSE trial, which looked at the use of empagliflozin in hospitalized patients with acute heart failure. The study found that patients randomly assigned to empagliflozin had a 36% chance of improved outcomes by 3 months.
He next looks at two reports from the EMPEROR-Preserved trials, which examined the effects of empagliflozin on patients with ejection fraction greater than 50%. The study found a 17% relative risk reduction in cardiovascular death and a 22% reduction in risk for first heart failure hospitalization. The second EMPEROR report, which examined quality-of-life metrics, found a benefit in favor of empagliflozin over placebo.
Next, Dr Butler discusses the CHIEF-HF trial, in which heart failure patients were randomly assigned to canagliflozin regardless of ejection fraction. Canagliflozin showed benefit in symptom improvement consistently, regardless of patients having diabetes or heart failure with reduced or preserved ejection fraction.
Finally, Dr Butler examined the results of the FIGARO-DKD trial, which studied finerenone in patients with diabetic kidney disease. The study reported a 32% relative risk reduction in heart failure events, and reduced hospitalization and cardiovascular death in patients who had a history of heart failure events and those who did not.
--
Javed Butler, MD, Professor, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi
Javed Butler, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott; Amgen; Array; AstraZeneca; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; CVRx; Janssen; LivaNova; Luitpold; Medtronic; Merck; Novartis; Novo Nordisk; Vifor
Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis; Boehringer-Ingelheim; Eli Lilly; Janssen
